{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:51:50Z","timestamp":1779299510978,"version":"3.51.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Mitotic regulators play an essential role in cell cycle progression by ensuring correct chromosomal alignment, segregation, DNA replication, repair, and division, thereby maintaining genomic stability. Aberrant activity of cell cycle kinases, including aurora kinase B (AURKB) and cyclin-dependent kinase 1 (CDK1), might lead to disrupted mitotic checkpoints, causing aneuploidies and uncontrolled proliferation, which are critical hallmarks of cancers. Targeted inhibition of cell cycle kinases is an attractive strategy to combat cancers with minimal side effects. This study employed a comprehensive multi-staged computational approach to discover dual-targeting inhibitors against AURKB and CDK1, which are reported as key promoters of tumorigenesis. High-throughput screening of phytochemicals available in the Indian Medicinal Plants, Phytochemistry, and Therapeutics (IMPPAT) database was conducted to identify common lead\/s from top hits. Jervine (IMPHY000366), a steroid alkaloid, emerged as a common compound depicting high binding affinity and ligand efficiency for AURKB and CDK1. In addition, this compound qualified all drug-like filters. After structure analysis, the docked complex was subjected to 300 ns MD simulation studies, confirming structural integrity in AURKB and CDK1 upon binding of Jervine. H-bonding pattern, secondary structural content, free energy landscape, and principal component analysis further supported Jervine\u2019s strong and stable affinity for AURKB and CDK1. Lastly, MMPBSA showed a higher negative free energy in the presence of Jervine than VX-680 when complexed with AURKB. Finally, our results suggest that Jervine is a potent, dual-targeting kinase inhibitor with favourable pharmacokinetic and therapeutic properties, warranting further experimental validation for anticancer drug development.<\/jats:p>","DOI":"10.3389\/fphar.2025.1662556","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:11Z","timestamp":1763706551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Structure-based identification of Jervine as a potent dual-targeting inhibitor of cell cycle kinases"],"prefix":"10.3389","volume":"16","author":[{"given":"Md Nayab","family":"Sulaimani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khadija","family":"Imtiyaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Imtaiyaz","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fohad Mabood","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aanchal","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mir Ovais","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anam","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravins","family":"Dohare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhwinder Singh","family":"Sohal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00432-021-03669-5","article-title":"Aurora B kinase: a potential drug target for cancer therapy","volume":"147","author":"Ahmed","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"114704","DOI":"10.1016\/j.ejmech.2022.114704","article-title":"Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer","volume":"243","author":"Akl","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1016\/j.ejmech.2010.06.034","article-title":"Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay","volume":"45","author":"Al-Sha\u2019er","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9463","DOI":"10.1080\/07391102.2023.2252086","article-title":"In silico identification of potential protein kinase C alpha inhibitors from phytochemicals from IMPPAT database for anticancer therapeutics: a virtual screening approach","volume":"42","author":"Alshehri","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B5","doi-asserted-by":"publisher","first-page":"7872","DOI":"10.1039\/d1ra09339h","article-title":"Bioactive phytoconstituents as potent inhibitors of casein kinase-2: dual implications in cancer and COVID-19 therapeutics","volume":"12","author":"Anjum","year":"2022","journal-title":"RSC Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"18707","DOI":"10.1038\/s41598-021-97368-3","article-title":"Exploration of the structural requirements of Aurora kinase B inhibitors by a combined QSAR, modelling and molecular simulation approach","volume":"11","author":"Ashraf","year":"2021","journal-title":"Sci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cbpa.2016.08.011","article-title":"Targeting biomolecules with reversible covalent chemistry","volume":"34","author":"Bandyopadhyay","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.biocel.2005.02.021","article-title":"Aurora kinases","volume":"37","author":"Bolanos-Garcia","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3390\/molecules26071981","article-title":"Aurora kinase B inhibition: a potential therapeutic strategy for cancer","volume":"26","author":"Borah","year":"2021","journal-title":"Molecules"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1038\/cddis.2012.148","article-title":"Mitosis-targeted anti-cancer therapies: where they stand","volume":"3","author":"Chan","year":"2012","journal-title":"Cell Death Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"110898","DOI":"10.1016\/j.biopha.2020.110898","article-title":"Jervine exhibits anticancer effects on nasopharyngeal carcinoma through promoting autophagic apoptosis via the blockage of Hedgehog signaling","volume":"132","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nchembio.1471","article-title":"Dual kinase-bromodomain inhibitors for rationally designed polypharmacology","volume":"10","author":"Ciceri","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1042\/0264-6021:3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors","volume":"351","author":"Davies","year":"2000","journal-title":"Biochem. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1021\/acs.jnatprod.4c00581","article-title":"Natural products have increased rates of clinical trial success throughout the drug development process","volume":"87","author":"Domingo-Fern\u00e1ndez","year":"2024","journal-title":"J. Nat. Prod."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/nejmoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.3390\/molecules26175324","article-title":"Scaffold repurposing of in-house small molecule candidates leads to discovery of first-in-class CDK-1\/HER-2 dual inhibitors: in vitro and in silico screening","volume":"26","author":"Elkamhawy","year":"2021","journal-title":"Molecules"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-4224673\/v1","article-title":"Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor \u03b2: an integrated docking and MD simulation approach","author":"Habib","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"1492847","DOI":"10.3389\/fmolb.2024.1492847","article-title":"Identification of potential bioactive phytochemicals for the inhibition of platelet-derived growth factor receptor \u03b2: a structure-based approach for cancer therapy","volume":"11","author":"Habib","year":"","journal-title":"Front. Mol. Biosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.1080\/07391102.2022.2154849","article-title":"Integrated virtual screening and MD simulation study to discover potential inhibitors of Lyn-kinase: targeting cancer therapy","volume":"41","author":"Hassan","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1553987","DOI":"10.3389\/fchem.2025.1553987","article-title":"Structure-based identification of bioactive phytochemicals targeting kallikrein-related peptidase 2 for prostate cancer therapy","volume":"13","author":"Jairajpuri","year":"2025","journal-title":"Front. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/bioinformatics\/btaa849","article-title":"PyMod 3: a complete suite for structural bioinformatics in PyMOL","volume":"37","author":"Janson","year":"2021","journal-title":"Bioinformatics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s44276-024-00064-8","article-title":"New light on chemotherapy toxicity and its prevention","volume":"2","author":"Juthani","year":"2024","journal-title":"BJC Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/cells9071568","article-title":"Role of cyclin-dependent kinase 1 in translational regulation in the M-phase","volume":"9","author":"Kalous","year":"2020","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2407-14-32","article-title":"Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4\/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells","volume":"14","author":"Kang","year":"2014","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1021\/acs.jnatprod.9b00372","article-title":"Identification of \u03b1-mangostin as a potential inhibitor of microtubule affinity regulating kinase 4","volume":"82","author":"Khan","year":"2019","journal-title":"J. Nat. Prod."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2174\/1568026621666211105095731","article-title":"High-resolution MD simulation studies to get mechanistic insights into the urea-induced denaturation of human sphingosine kinase 1","volume":"21","author":"Khan","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fcell.2015.00014","article-title":"The chromosomal passenger complex (CPC) as a key orchestrator of orderly mitotic exit and cytokinesis","volume":"3","author":"Kitagawa","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jbiotec.2020.07.015","article-title":"Contribution of secondary structure changes to the surface activity of proteins","volume":"323","author":"Koop","year":"2020","journal-title":"J. Biotechnol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bioinformatics\/16.8.747","article-title":"PASS: prediction of activity spectra for biologically active substances","volume":"16","author":"Lagunin","year":"2000","journal-title":"Bioinformatics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bbrc.2020.08.023","article-title":"Jervine inhibits non-small cell lung cancer (NSCLC) progression by suppressing Hedgehog and AKT signaling via triggering autophagy-regulated apoptosis","volume":"533","author":"Lei","year":"2020","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1134\/s0026893308040195","article-title":"Radius of gyration as an indicator of protein structure compactness","volume":"42","author":"Lobanov","year":"2008","journal-title":"Mol. Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1182\/blood-2011-07-366930","article-title":"Phase 1\/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia","volume":"118","author":"L\u00f6wenberg","year":"2011","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2011.197","article-title":"Killing cells by targeting mitosis","volume":"19","author":"Manchado","year":"2012","journal-title":"Cell Death Differ."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.ijbiomac.2020.08.057","article-title":"Impact of amino acid substitution in the kinase domain of Bruton tyrosine kinase and its association with X-linked agammaglobulinemia","volume":"164","author":"Mohammad","year":"","journal-title":"Int. J. Biol. Macromol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/molecules25040823","article-title":"Virtual screening approach to identify high-affinity inhibitors of serum and glucocorticoid-regulated kinase 1 among bioactive natural products: combined molecular docking and simulation studies","volume":"25","author":"Mohammad","year":"","journal-title":"Molecules"},{"key":"B42","doi-asserted-by":"publisher","first-page":"bbaa279","DOI":"10.1093\/bib\/bbaa279","article-title":"InstaDock: a single-click graphical user interface for molecular docking-based virtual high-throughput screening","volume":"22","author":"Mohammad","year":"2021","journal-title":"Briefings Bioinforma."},{"key":"B43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/acsmedchemlett.6b00518","article-title":"Design and synthesis of potent and selective PIM kinase inhibitors by targeting unique structure of ATP-binding pocket","volume":"8","author":"Nakano","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2174\/1568026618666181025114157","article-title":"Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships","volume":"18","author":"Naqvi","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/biology6010012","article-title":"The consequences of chromosome segregation errors in mitosis and meiosis","volume":"6","author":"Potapova","year":"2017","journal-title":"Biology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"139107","DOI":"10.1016\/j.ijbiomac.2024.139107","article-title":"FDA-approved drugs as PIM-1 kinase inhibitors: a drug repurposed approach for cancer therapy","volume":"292","author":"Rathi","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/nu15081896","article-title":"Phytochemicals in cancer treatment and cancer prevention\u2014review on epidemiological data and clinical trials","volume":"15","author":"Rudzi\u0144ska","year":"2023","journal-title":"Nutrients"},{"key":"B49","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.coph.2010.09.016","article-title":"Molecular dynamics simulations of protein dynamics and their relevance to drug discovery","volume":"10","author":"Salsbury","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.36922\/imo.6547","article-title":"Computational identification and molecular characterization of novel Aurora-B kinase inhibitors: pharmacophore modeling, docking, and molecular dynamics simulations","volume":"2","author":"Selvam","year":"2025","journal-title":"Innovative Med. Omics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3171\/jns.1992.76.4.0571","article-title":"Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial","volume":"76","author":"Shibuya","year":"1992","journal-title":"J. Neurosurg."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1158\/1078-0432.CCR-05-1964","article-title":"PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity","volume":"12","author":"Soncini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1535-7163.MCT-08-0890","article-title":"Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines","volume":"8","author":"Squires","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0311954","DOI":"10.1371\/journal.pone.0311954","article-title":"Structure-guided identification of mitogen-activated protein kinase-1 inhibitors towards anticancer therapeutics","volume":"20","author":"Sulaimani","year":"2025","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/molecules26030651","article-title":"Druggable transient pockets in protein kinases","volume":"26","author":"Umezawa","year":"2021","journal-title":"Molecules"},{"key":"B56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","article-title":"Targeting CDK1 in cancer: mechanisms and implications","volume":"7","author":"Wang","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1158\/1078-0432.CCR-06-2979","article-title":"AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis","volume":"13","author":"Wilkinson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B58","volume-title":"Pre-clinical evaluation of a small molecule inhibitor of CDK1 as potential therapy for MYC expressing multiple myeloma tumors","author":"Zeng","year":"2008"},{"key":"B59","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1662556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:15Z","timestamp":1763706555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1662556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":59,"alternative-id":["10.3389\/fphar.2025.1662556"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1662556","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1662556"}}